Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
Journal of Antimicrobial Chemotherapy · 01.12.2023 · 78 (12) · 2795-2800
DOI: 10.1093/jac/dkad225 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 16.10.2023. Verfasst von Su Young Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, West Coast University, 590 N. Vermont Ave, Los Angeles, CA 90004, USA. Hauptthemen laut MEDLINE: Ceftazidime, Carbapenems. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Center for Anti-Infective Research.
Abstract (Originalsprache)
Background
Antimicrobial resistance in Pseudomonas aeruginosa is complex and multifaceted. While the novel β-lactamase inhibitors (BLIs) avibactam, relebactam and vaborbactam inhibit serine-based β-lactamases, the comparative potency of the novel β-lactam (BL)/BLI combinations against serine carbapenemase-producing P. aeruginosa is unknown.
Objectives
To compare the in vitro activity of ceftazidime/avibactam, ceftazidime, imipenem/relebactam, imipenem, meropenem/vaborbactam and meropenem against serine β-lactamase-producing P. aeruginosa.
Methods
Carbapenem-resistant P. aeruginosa were collated through the Enhancing Rational Antimicrobials against Carbapenem-resistant P. aeruginosa (ERACE-PA) Global Surveillance. Isolates positive for serine-based carbapenemases were assessed. MICs were determined by broth microdilution to each novel BL/BLI and BL alone.
Results
GES was the most common carbapenemase identified (n = 59) followed by KPC (n = 8). Ceftazidime/avibactam had MIC50/MIC90 values of 4/8 mg/L and 91% of isolates were susceptible. Conversely, ceftazidime alone was active against only 3% of isolates. The MIC50/MIC90 of imipenem/relebactam were 16/>16 mg/L and 13% of all isolates were defined as susceptible. Of the KPC-producing isolates, 38% were susceptible to imipenem/relebactam, compared with 0% to imipenem. The meropenem/vaborbactam MIC50/MIC90 were >16/>16 mg/L, and 6% of isolates were susceptible, which was similar to meropenem alone (MIC50/90, >8/>8 mg/L; 3% susceptible) suggesting the addition of vaborbactam cannot overcome co-expressed, non-enzymatic resistance mechanisms.
Conclusions
Among the novel BL/BLIs, ceftazidime/avibactam displayed better in vitro activity and thus is a rational treatment option for serine carbapenemase-harbouring P. aeruginosa. While imipenem/relebactam displayed some activity, particularly against isolates with blaKPC, meropenem/vaborbactam exhibited poor activity, with MICs similar to meropenem alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, West Coast University, 590 N. Vermont Ave, Los Angeles, CA 90004, USA.
- Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
- Division of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
ORCID-Profile: Su Young Lee, Christian M Gill, David P Nicolau
Förderung
- Center for Anti-Infective Research
Zitieren
APA
Lee, S. Y., Gill, C. M., Nicolau, D. P., & ERACE-PA Global Study Group (2023). Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 78(12), 2795-2800. https://doi.org/10.1093/jac/dkad225
Vancouver
Lee SY, Gill CM, Nicolau DP, ERACE-PA Global Study Group. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2023;78(12):2795-2800. doi:10.1093/jac/dkad225
BibTeX
@article{Lee2023,
author = {Lee, Su Young and Gill, Christian M and Nicolau, David P and ERACE-PA Global Study Group, ERACE-PA Global Study Group},
title = {Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
volume = {78},
number = {12},
pages = {2795--2800},
doi = {10.1093/jac/dkad225}
}
EUVIMED